SenoRx Announces CE Mark Approval for Its SenoSonix With EnCor Breast Biopsy Ultrasound...

SenoRx Announces CE Mark Approval for Its SenoSonix With EnCor Breast Biopsy
Ultrasound System

ALISO VIEJO, Calif., April 10, 2008 (PRIME NEWSWIRE) -- SenoRx, Inc.
(Nasdaq:SENO) today announced that it has received approval to apply the CE Mark
to its SenoSonix(tm) with EnCor, an integration of its EnCor(r) breast biopsy
system with a state-of-the-art ultrasound imaging system. The device
incorporates SenoRx's proprietary EnCor vacuum-assisted biopsy technologies with
an ultrasound system developed and sold by Ultrasonix Medical Corporation of
Canada. The CE Mark is required for sales in countries within the European
Economic Community. SenoRx and Ultrasonix had previously announced the receipt
of 510(k) clearance in the United States for the SenoSonix system in October
2007.

Launching its EnCor system in November 2005, SenoRx currently has an installed
base of more than 500 of its breast biopsy systems in the United States and
Canada. SenoRx began launching the EnCor system in Europe during the fourth
quarter of 2007. Ultrasonix launched its innovative Sonix series of Smart
Ultrasound systems in 2005 and has placed over 1,000 systems worldwide.

"Having the right to apply the CE Mark to the SenoSonix system further
strengthens our EnCor product platform. While we are positioning SenoSonix with
EnCor to compete in the breast surgeon's office in the United States, we also
believe that the value and convenience proposition for this product may also be
compelling in markets outside the U.S. where a significant percentage of biopsy
procedures utilize ultrasound imaging. We believe that the SenoSonix system may
uniquely address the breast biopsy market with a cost-effective solution that
provides high-quality ultrasound imaging and guidance with vacuum-assisted
breast biopsy capability in one device," said Lloyd Malchow, SenoRx President
and Chief Executive Officer. "Full commercial launch of the product began in the
U.S. in February 2008 and will be launched in April in select European Economic
Community countries."

About SenoRx

SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical
devices used by breast care specialists for the diagnosis and treatment of
breast cancer, including its flagship EnCor(r) system and Contura(tm) MLB.
SenoRx's field sales organization serves over 1,000 breast diagnostic and
treatment centers in the United States and Canada. The company's line of breast
care products includes biopsy disposables, biopsy capital equipment, diagnostic
adjunct products and therapeutic disposables. SenoRx is developing additional
minimally invasive products for the diagnosis and treatment of breast cancer.
For more information, visit the company's website at www.senorx.com.

The SenoRx, Inc. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=3605

About Ultrasonix

Ultrasonix Medical is a privately held company based in Richmond, British
Columbia, Canada focusing on development and manufacturing of high quality
diagnostic ultrasound imaging systems. Ultrasonix brings "smart" ultrasound
equipment and capabilities into private medical practices, clinics and hospitals
alike. The company's award-winning devices incorporate high-quality imaging with
unique workflow and data management features in an easy to use platform. Through
its innovative products and features, Ultrasonix continues to deliver on its
mission of providing better patient care making it a natural fit for the Breast
Imaging market. Further information is available at www.ultrasonix.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements
concerning SenoSonix with EnCor, including the ability to competitively position
it in the physician office and other markets, its expected value proposition and
convenience in markets, including outside the United States, its
cost-effectiveness and its expected attractiveness to physicians are
forward-looking statements within the meaning of the Safe Harbor.
Forward-looking statements are based on management's current, preliminary
expectations and are subject to risks and uncertainties, which may cause
SenoRx's actual results to differ materially from the statements contained
herein. Information on potential risk factors that could affect SenoRx's
business and its financial results are detailed in its most recent annual report
on Form 10-K for the year ended December 31, 2007, as filed with the Securities
and Exchange Commission. Undue reliance should not be placed on forward-looking
statements, especially guidance on future financial performance, which speaks
only as of the date they are made. SenoRx undertakes no obligation to update
publicly any forward-looking statements to reflect new information, events or
circumstances after the date they were made, or to reflect the occurrence of
unanticipated events.

-0-
CONTACT: SenoRx, Inc.
Lila Churney, Director of Investor Relations
949.362.4800 ext.132

Ultrasonix Medical
Barbara Del Prince, General Manager Global Marketing
604.279.8550 ext.160